Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Cancer and Oncology›Teratocarcinoma
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Teratocarcinoma

Cancer and Oncology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A malignant neoplasm consisting of elements of teratoma with those of embryonal carcinoma or choriocarcinoma, or both.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (1,053 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A malignant neoplasm consisting of elements of teratoma with those of embryonal carcinoma or choriocarcinoma, or both. It occurs most often in the testis. (Dorland, 27th ed)

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Teratocarcinomas.

Where it fits in the MeSH classification

Broader topics
Neoplasms, Germ Cell and Embryonal

Research landscape

PubMed indexes 737 records tagged with the MeSH heading “Teratocarcinoma” (counts retrieved 2026-10-29). 19 of them (2.6%) were published from 2020 onward, and the busiest period so far is through 1999 with 329 records.

Reviews account for 44 records (6.0%) and meta-analyses for 0. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 329 records; 2000-2009: 290 records; 2010-2019: 99 records; 2020 onward: 19 records329through 19992902000-2009992010-2019192020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 1999329
2000-2009290
2010-201999
2020 onward19
Share of records by publication typeReviews: 6.0 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 0.0 percentReviews6.0% (44)Meta-analyses0.0% (0)Randomized controlled trials0.0% (0)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 737 PubMed records
TypeRecordsShare
Reviews446.0%
Meta-analyses00.0%
Randomized controlled trials00.0%

Method: PubMed query "Teratocarcinoma"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in cancer and oncology

Cancer research spans very different kinds of evidence. Laboratory studies in cell lines and animal models reveal mechanisms but often do not translate to patients. Early-phase trials mainly test safety and dosing, while phase 3 randomized trials and their meta-analyses are the usual basis for treatment conclusions. Outcomes also differ in meaning: tumour shrinkage, progression-free survival and overall survival are not interchangeable, and screening studies can be distorted by lead-time and overdiagnosis. When reading a result, check the cancer type and stage studied, the comparison treatment, and which outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors
Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA
2012Research article
Design not recorded in structured metadata
224cc by
PMID 22273460 · DOI · PMC3314544
Differential expression of HERV-K (HML-2) proviruses in cells and virions of the teratocarcinoma cell line Tera-1
Bhardwaj N, Montesion M, Roy F, Coffin JM
2015Research article
Design not recorded in structured metadata
62cc by
PMID 25746218 · DOI · PMC4379556
Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines
Schröpfer A, Kammerer U, Kapp M, Dietl J, Feix S, Anacker J
2010Research article
Design not recorded in structured metadata
60cc by
PMID 20942921 · DOI · PMC2964638
Comparative immunohistochemical characterisation of a teratoma in a domestic duck (Anas platyrhynchos) and a teratocarcinoma in a muscovy duck (Cairina moschata)
Eikelberg DJ, Stoff M, Peters M, Legler M, Gerhauser I, Wohlsein P
2025Research article
Design not recorded in structured metadata
0cc by
PMID 40217475 · DOI · PMC11987307

Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors [1]

Research article Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA · · 2012 · cited 224 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundSeveral stromal cell subtypes including macrophages contribute to tumor progression by inducing epithelial-mesenchymal transition (EMT) at the invasive front, a mechanism also linked to metastasis.
Closing excerpt
As macrophage infiltration and pronounced EMT tumor phenotype correlate with increased grade in NSCLC patients, we propose that TAMs also promote tumor progression by inducing EMT locally in tumors.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (320 words)

BackgroundSeveral stromal cell subtypes including macrophages contribute to tumor progression by inducing epithelial-mesenchymal transition (EMT) at the invasive front, a mechanism also linked to metastasis. Tumor associated macrophages (TAM) reside mainly at the invasive front but they also infiltrate tumors and in this process they mainly assume a tumor promoting phenotype. In this study, we asked if TAMs also regulate EMT intratumorally. We found that TAMs through TGF-β signaling and activation of the β-catenin pathway can induce EMT in intratumoral cancer cells.MethodsWe depleted macrophages in F9-teratocarcinoma bearing mice using clodronate-liposomes and analyzed the tumors for correlations between gene and protein expression of EMT-associated and macrophage markers. The functional relationship between TAMs and EMT was characterized in vitro in the murine F9 and mammary gland NMuMG cells, using a conditioned medium culture approach. The clinical relevance of our findings was evaluated on a tissue microarray cohort representing 491 patients with non-small cell lung cancer (NSCLC).ResultsGene expression analysis of F9-teratocarcinomas revealed a positive correlation between TAM-densities and mesenchymal marker expression. Moreover, immunohistochemistry showed that TAMs cluster with EMT phenotype cells in the tumors. In vitro, long term exposure of F9-and NMuMG-cells to macrophage-conditioned medium led to decreased expression of the epithelial adhesion protein E-cadherin, activation of the EMT-mediating β-catenin pathway, increased expression of mesenchymal markers and an invasive phenotype. In a candidate based screen, macrophage-derived TGF-β was identified as the main inducer of this EMT-associated phenotype. Lastly, immunohistochemical analysis of NSCLC patient samples identified a positive correlation between intratumoral macrophage densities, EMT markers, intraepithelial TGF-β levels and tumor grade.ConclusionsData presented here identify a novel role for macrophages in EMT-promoted tumor progression. The observation that TAMs cluster with intra-epithelial fibroblastoid cells suggests that the role of macrophages in tumor-EMT extends beyond the invasive front. As macrophage infiltration and pronounced EMT tumor phenotype correlate with increased grade in NSCLC patients, we propose that TAMs also promote tumor progression by inducing EMT locally in tumors.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 22273460 · DOI · PMC3314544

Differential expression of HERV-K (HML-2) proviruses in cells and virions of the teratocarcinoma cell line Tera-1 [2]

Research article Bhardwaj N, Montesion M, Roy F, Coffin JM · · 2015 · cited 62 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Human endogenous retrovirus (HERV-K (HML-2)) proviruses are among the few endogenous retroviral elements in the human genome that retain coding sequence.
Closing excerpt
Consistent with the RNASeq results, we found that the activity of most LTRs corresponded to their transcript levels.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (179 words)

Human endogenous retrovirus (HERV-K (HML-2)) proviruses are among the few endogenous retroviral elements in the human genome that retain coding sequence. HML-2 expression has been widely associated with human disease states, including different types of cancers as well as with HIV-1 infection. Understanding of the potential impact of this expression requires that it be annotated at the proviral level. Here, we utilized the high throughput capabilities of next-generation sequencing to profile HML-2 expression at the level of individual proviruses and secreted virions in the teratocarcinoma cell line Tera-1. We identified well-defined expression patterns, with transcripts emanating primarily from two proviruses located on chromosome 22, only one of which was efficiently packaged. Interestingly, there was a preference for transcripts of recently integrated proviruses, over those from other highly expressed but older elements, to be packaged into virions. We also assessed the promoter competence of the 5' long terminal repeats (LTRs) of expressed proviruses via a luciferase assay following transfection of Tera-1 cells. Consistent with the RNASeq results, we found that the activity of most LTRs corresponded to their transcript levels.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25746218 · DOI · PMC4379556

Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines [3]

Research article Schröpfer A, Kammerer U, Kapp M, Dietl J, Feix S, Anacker J · · 2010 · cited 60 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundMatrix metalloproteinases (MMPs) are involved in the degradation of protein components of the extracellular matrix and thus play an important role in tumor invasion and metastasis.
Closing excerpt
ConclusionsIshikawa, Caski, OAW-42 and BeWo cell lines could be the best choice for all future experiments on MMP regulation and their role in endometrial, cervical, ovarian or choriocarcinoma development, whereas the teratocarcinoma cell line PA1 could be used as a positive control for general MMP experiments.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (272 words)

BackgroundMatrix metalloproteinases (MMPs) are involved in the degradation of protein components of the extracellular matrix and thus play an important role in tumor invasion and metastasis. Their expression is related to the progression of gynecological cancers (e.g. endometrial, cervical or ovarian carcinoma). In this study we investigated the expression pattern of the 23 MMPs, currently known in humans, in different gynecological cancer cell lines.MethodsIn total, cell lines from three endometrium carcinomas (Ishikawa, HEC-1-A, AN3 CA), three cervical carcinomas (HeLa, Caski, SiHa), three chorioncarcinomas (JEG, JAR, BeWo), two ovarian cancers (BG-1, OAW-42) and one teratocarcinoma (PA-1) were examined. The expression of MMPs was analyzed by RT-PCR, Western blot and gelatin zymography.ResultsWe demonstrated that the cell lines examined can constitutively express a wide variety of MMPs on mRNA and protein level. While MMP-2, -11, -14 and -24 were widely expressed, no expression was seen for MMP-12, -16, -20, -25, -26, -27 in any of the cell lines. A broad range of 16 MMPs could be found in the PA1 cells and thus this cell line could be used as a positive control for general MMP experiments. While the three cervical cancer cell lines expressed 10-14 different MMPs, the median expression in endometrial and choriocarcinoma cells was 7 different enzymes. The two investigated ovarian cancer cell lines showed a distinctive difference in the number of expressed MMPs (2 vs. 10).ConclusionsIshikawa, Caski, OAW-42 and BeWo cell lines could be the best choice for all future experiments on MMP regulation and their role in endometrial, cervical, ovarian or choriocarcinoma development, whereas the teratocarcinoma cell line PA1 could be used as a positive control for general MMP experiments.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 20942921 · DOI · PMC2964638

Comparative immunohistochemical characterisation of a teratoma in a domestic duck (Anas platyrhynchos) and a teratocarcinoma in a muscovy duck (Cairina moschata) [4]

Research article Eikelberg DJ, Stoff M, Peters M, Legler M, Gerhauser I, Wohlsein P · · 2025

Abstract reading summary — source excerpts
Opening excerpt
BackgroundNeoplasms consisting of two or more germinal layers are classified as teratomas if benign or as teratocarcinomas if malignant.
Closing excerpt
During these examinations, a large spectrum of antibodies specific for different tissues and cells were tested on duck control tissue which can be of help for immunohistochemical examinations on avian tissues in the future.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (282 words)

BackgroundNeoplasms consisting of two or more germinal layers are classified as teratomas if benign or as teratocarcinomas if malignant. Teratomas are rare tumours occurring in a wide range of species including mammals, birds and reptiles and only a few cases have been reported in ducks with infrequent documentation of immunohistochemical characterisation. Teratocarcinomas occur rarely and, to the authors' knowledge, have not been described or immunohistochemically characterised in ducks, yet. Therefore, the clinical and pathological presentation of a teratoma in a mulard duck and a teratocarcinoma in a muscovy duck are described. In addition to a histologic examination, both tumours were characterised by applying a panel of immunohistochemical markers previously tested on duck tissue.Case presentationA mulard duck (Anas platyrhynchos x Cairina moschata) showed a mass in the cranial coelomic cavity histologically diagnosed as tridermic teratoma. A caudal coelomic mass in a Muscovy duck (Cairina moschata) was histologically diagnosed as a teratocarcinoma with metastases to the liver, mesentery and intestinal wall. An extensive immunohistochemical examination for a detailed characterisation and comparison with duck control tissue was performed in both cases, highlighting various components of the neoplastic tissues including lymphocytes, nervous and endodermal components.ConclusionsTo the authors' knowledge, this is the first report of a teratocarcinoma in a duck with intense immunohistochemical characterisation and comparison with a teratoma in another duck. Immunohistochemistry enables a more profound examination of the histogenetic composition of such neoplasms compared to histology alone. Both neoplasms should be considered as differentials for masses in body cavities of ducks. During these examinations, a large spectrum of antibodies specific for different tissues and cells were tested on duck control tissue which can be of help for immunohistochemical examinations on avian tissues in the future.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40217475 · DOI · PMC11987307

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Self-renewal of teratocarcinoma and embryonic stem cells [5]
    Chambers I, Smith A · Oncogene · 2004 · cited 379 times (Europe PMC)
  • Research article The tumorigenicity of human embryonic stem cells [6]
    Blum B, Benvenisty N · Adv Cancer Res · 2008 · cited 299 times (Europe PMC)
  • Research article Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers [7]
    Sell S, Pierce GB · Lab Invest · 1994 · cited 236 times (Europe PMC)
  • Research article From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research [8]
    Solter D · Nat Rev Genet · 2006 · cited 202 times (Europe PMC)
  • Research article From teratocarcinomas to embryonic stem cells [9]
    Andrews PW · Philos Trans R Soc Lond B Biol Sci · 2002 · cited 178 times (Europe PMC)
  • Research article The tumorigenicity of diploid and aneuploid human pluripotent stem cells [10]
    Blum B, Benvenisty N · Cell Cycle · 2009 · cited 93 times (Europe PMC)

References

  1. Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. . 2012. PMID 22273460 · DOI · PMC3314544
  2. Bhardwaj N, Montesion M, Roy F, Coffin JM. Differential expression of HERV-K (HML-2) proviruses in cells and virions of the teratocarcinoma cell line Tera-1. . 2015. PMID 25746218 · DOI · PMC4379556
  3. Schröpfer A, Kammerer U, Kapp M, Dietl J, Feix S, Anacker J. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. . 2010. PMID 20942921 · DOI · PMC2964638
  4. Eikelberg DJ, Stoff M, Peters M, Legler M, Gerhauser I, Wohlsein P. Comparative immunohistochemical characterisation of a teratoma in a domestic duck (Anas platyrhynchos) and a teratocarcinoma in a muscovy duck (Cairina moschata). . 2025. PMID 40217475 · DOI · PMC11987307
  5. Chambers I, Smith A. Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene. 2004. PMID 15378075 · DOI
  6. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008. PMID 18620095 · DOI
  7. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest. 1994. PMID 8302019
  8. Solter D. From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Nat Rev Genet. 2006. PMID 16534514 · DOI
  9. Andrews PW. From teratocarcinomas to embryonic stem cells. Philos Trans R Soc Lond B Biol Sci. 2002. PMID 12028783 · DOI · PMC1692959
  10. Blum B, Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle. 2009. PMID 19887907 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Carcinoid TumorCancer and Oncology
  • ChordomaCancer and Oncology
  • ChoriocarcinomaCancer and Oncology
  • CraniopharyngiomaCancer and Oncology
  • Cutaneous Malignant MelanomaCancer and Oncology
  • Dermoid CystCancer and Oncology

All 107 articles in Cancer and Oncology →

At a glance

737
PubMed records on this heading
3%
published since 2020
44
review articles
0
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Carcinoid TumorCancer and Oncology
  • ChordomaCancer and Oncology
  • ChoriocarcinomaCancer and Oncology
  • CraniopharyngiomaCancer and Oncology
  • Cutaneous Malignant MelanomaCancer and Oncology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support